TICKERNERD
Menu
VTGNVTGNHealthcare · Biotechnology

VTGN Stock Forecast: VistaGen Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 17 Aug 2026
$0.26
−3.70% on the day

The 4 Wall Street analysts covering VistaGen Therapeutics, Inc. hold a median 12-month price target of $1 — +284.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 17 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$11.9M
Ticker Nerd rank
19 / 100
Median analyst target
$1.00
Analysts covering
4
Total return, dividends reinvested
1W
0.0%
1M
+13.0%
YTD
−60.6%
1Y
−92.1%
From 52W high
−94.7%
From 52W low
+13.0%
$0.23
$4.90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VTGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores VistaGen Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Aug 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
92
Accruals
79
Issuance
48
Volatility
47
Revisions
34
Quality
17
Momentum
16
Growth
8
Value
4

Size (92): Smaller than most of the companies we track.

Value (4): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VTGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VTGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26VTGNHigh $1.00Median $1.00Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
0 Buy4 Hold0 Sell
Low $1.00Median $1.00High $1.00

The green dot is the last close — the median target sits +284.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Dec 2025JefferiesDowngradeHold$15 → $0.90
17 Dec 2025Maxim GroupDowngradeHold—
17 Dec 2025William BlairDowngradeMarket Perform—
7 Dec 2023JefferiesUpgradeBuy—
14 Nov 2023StifelInitiatesBuy—
5 Sept 2023Maxim GroupMaintainsBuy—
7 Aug 2023Maxim GroupUpgradeBuy—
26 July 2022Maxim GroupDowngradeHold—
22 July 2022William BlairDowngradeMarket Perform—
20 May 2021BairdInitiatesOutperform—
18 Feb 2021JefferiesInitiatesBuy—
4 Jan 2021William BlairUpgradeOutperform—
8 Oct 2020Aegis CapitalInitiatesBuy—
28 Aug 2019William BlairInitiatesOutperform—
22 July 2019Chardan CapitalDowngradeNeutral$22 → $0.70
27 June 2018Maxim GroupInitiatesBuy—
24 May 2018OppenheimerInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VTGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

VTGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

VistaGen Therapeutics, Inc. (VTGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
9.4×

Cheaper than 15% of US stocks

Price / book
0.3×

Cheaper than 88% of US stocks

EV / EBITDA
0.5×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
53.5%

Higher than 87% of US stocks

Earnings growth (YoY)
−3200.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−3595.1%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−131.6%

Higher than 10% of US stocks

Return on assets
−67.8%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

VTGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VTGNVistaGen Therapeutics, Inc.$11.9M
19
KPRXKiora Pharmaceuticals, Inc.$11.5M
72
MBRXMoleculin Biotech, Inc.$11.8M
21
PDSBPDS Biotechnology Corp.$12.1M
62
TOVXTheriva Biologics, Inc.$10.9M
27
ASBPAspire Biopharma Holdings, Inc.$10.9M
15
INABIN8bio, Inc.$10.8M
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own VistaGen Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VTGN news & analysis

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

GlobeNewsWire · 14 Aug 2026positive

Vistagen reported its fiscal year 2027 first quarter financial results and provided a corporate update. Exploratory analyses of patients with very severe social anxiety disorder showed nominally statistically significant improvement in recently reported clinical studies.

Why it matters — VTGN watchers would care because the positive exploratory data in very severe social anxiety disorder could signal a potential pathway for the company's lead clinical program.

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

GlobeNewsWire · 6 Aug 2026positive

Vistagen announced topline results from its exploratory Phase 2 repeat dose study of fasedienol nasal spray for the acute treatment of social anxiety disorder in adults. The repeat dose demonstrated favorable safety and tolerability similar to single dose, with efficacy signals across primary and secondary endpoints and a prespecified analysis showing nominally statistically significant improvement in patients with very severe social anxiety disorder.

Why it matters — The results provide additional supportive evidence for Vistagen's planned discussions with the FDA regarding the fasedienol registrational pathway, a key step for the company's lead product candidate.

Vistagen Appoints Douglas J. Williamson to its Board of Directors

GlobeNewsWire · 31 July 2026neutral

Vistagen announced the appointment of Douglas J. Williamson to its Board of Directors. Williamson joins the board of the late clinical-stage biopharmaceutical company focused on intranasal neuroscience therapies.

Why it matters — A new board appointment may signal fresh strategic oversight as Vistagen advances its pherine-based intranasal product candidates through clinical development.

FAQ

Frequently asked questions about VTGN stock

What is the VTGN stock price forecast for 2026-2027?

The 4 Wall Street analysts covering VistaGen Therapeutics, Inc. have a median 12-month price target of $1, with estimates ranging from $1 to $1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VTGN stock a buy right now?

Of the 4 analysts covering VistaGen Therapeutics, Inc., 0 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks VistaGen Therapeutics, Inc. 19 out of 100 across roughly 4,600 US stocks as at 17 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VTGN?

As at 17 Aug 2026, VistaGen Therapeutics, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).

Will VTGN stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +284.6% from the last close, and Ticker Nerd's factor model ranks VistaGen Therapeutics, Inc. 19 out of 100 as at 17 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VTGN stock forecast for 2030?

No analyst covering VistaGen Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VTGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $1 over the next 12 months.

How has VTGN stock performed over the past year?

VistaGen Therapeutics, Inc. returned -92.1% over the 12 months to 17 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does VistaGen Therapeutics, Inc. do?

VistaGen Therapeutics Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for neuropsychiatric and neurological disorders using nose-to-brain neurocircuitry.

What is the latest news on VTGN?

The most recent item we track (GlobeNewsWire, 14 Aug 2026): "Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update". Vistagen reported its fiscal year 2027 first quarter financial results and provided a corporate update. Exploratory analyses of patients with very severe social anxiety disorder showed nominally statistically significant improvement in recently reported clinical studies.

Company

About VistaGen Therapeutics, Inc.

VistaGen Therapeutics Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for neuropsychiatric and neurological disorders using nose-to-brain neurocircuitry. The company pioneers pherine-based nasal spray technologies, with its lead candidate Fasedienol in Phase III clinical trials for the acute treatment of anxiety in adults with social anxiety disorder. Another key investigational product, Itruvone, is advancing in Phase II trials for major depressive disorder. VistaGen Therapeutics Inc. also explores additional pipeline candidates like PH284 for cancer cachexia and AV-101 for neuropathic pain, targeting unmet needs in mental health and neurology. These odorless, synthetic neuroactive pherines aim to provide rapid, non-systemic interventions by directly modulating brain neurocircuits via the nasal pathway. Founded in 2008 and headquartered in South San Francisco, California, VistaGen Therapeutics Inc. plays a significant role in advancing neuroscience innovations for disorders affecting millions worldwide, emphasizing clinical advancement and strategic presentations at key industry conferences.

CEO Mr. Shawn K. Singh J.D. · 41 employees · United States · https://www.vistagen.com